VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01
Glioblastoma
DRUG: VXM01
Safety and tolerability taking into account treatment-limiting toxicities (TLTs), AEs listed together with information on onset, duration, severity, seriousness, relationship to the study drug, relationship to chemotherapy and to the underlying disease, outcome, and action taken. Frequency tables by System Organ Class and preferred term., 12 months
Immune Response by Enzyme Linked Immuno Spot (ELISpot), Patient-individual VEGFR-2 specific T cell responses will be determined by ELISpot using cryopreserved peripheral blood mononuclear cells, 12 months|Serum biomarker Response by Enzyme Linked Immuno Sorbent Assay (ELISA), Biomarkers including VEGF A and Collagen IV determined from periphaeral blood samples, 12 months|Vascular normalization index (VNI) including tumor perfusion acc. to Sorensen 2009, Determined by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) (ktrans), dynamic susceptibility contrast imaging (DSC), blood volume maps (cerebral blood volume \[CBV\] of smaller vessels) and collagen IV, 12 months|Tumor immune cell infiltration by tumor tissue immunohistochemistry, Tumor tissue immunohistochemistry staining including Evaluations of effector T cell infiltration, regulatory T-cells (Treg), myeloid derived suppressor cells (MDSC), 35 days|Tumor response or progression on MRI acc. to Response Assessment in Neuro-Oncology (RANO) criteria, MRI comprising the National Brain Tumor Society /EORTC protocol for gliomas, 12 months|Clinical Response including time to progression, progression free survival, overall survival, 12 months|Biodistribution and shedding of VXM01 bacteria, Bacterial vector tissue biodistribution, persistence, and shedding of viable Ty21a bacteria (VXM01) determined by cultivation of stool samples, 10 days
VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01